Loading…
Cumberland Pharmaceuticals Inc. is projected to rise to $9.58 by 2027, a +43% move from its current price of $6.68. CPIX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/3/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 5 | $6.38 | $6.69 | $7.01 | +0.09% |
| Aug 6 | $6.26 | $6.69 | $7.15 | +0.18% |
| Aug 7 | $6.17 | $6.70 | $7.27 | +0.27% |
| Aug 8 | $6.10 | $6.70 | $7.37 | +0.37% |
| Aug 9 | $6.04 | $6.71 | $7.46 | +0.46% |
| Aug 10 | $5.98 | $6.72 | $7.54 | +0.55% |
| Aug 11 | $5.93 | $6.72 | $7.62 | +0.64% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $5.93 | $6.72 | $7.62 | +0.64% |
| Week 2 | $5.67 | $6.77 | $8.07 | +1.29% |
| Week 3 | $5.48 | $6.81 | $8.46 | +1.94% |
| Week 4 | $5.34 | $6.85 | $8.80 | +2.59% |
| Week 5 | $5.21 | $6.90 | $9.12 | +3.25% |
| Week 6 | $5.11 | $6.94 | $9.43 | +3.91% |
| Week 7 | $5.02 | $6.99 | $9.72 | +4.58% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development, and commercialization of prescription products. Its portfolio includes Acetadote, an injection for the treatment of acetaminophen poisoning; Caldolor, an injection for the treatment of pain and fever; Kristalose, a prescription laxative oral solution for the treatment of constipation; Sancuso, a transdermal patch for the prevention of nausea and vomiting in patients receiving chemotherapy treatment; Vaprisol, an injection to raise serum sodium levels in hospitalized patients with euvolemic and hypervolemic hyponatremia; Vibativ, an injection for the treatment of certain bacterial infections, including hospital-acquired and ventilator-associated bacterial pneumonia, as well as complicated skin and skin structure infections; and Tacilia, an oral capsule for the treatment of H.
pylori infection. It also develops ifetroban, a product candidate that has completed Phase II clinical trials for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, hepatorenal syndrome, portal hypertension, aspirin-exacerbated respiratory disease, systemic sclerosis, and idiopathic pulmonary fibrosis. It serves hospital acute care, gastroenterology, and oncology markets in the United States, China, South Korea, Russia, Mexico, Australia, and Saudi Arabia.
The company has a strategic alliance agreement with WinHealth Pharma Group Co. Limited. Cumberland Pharmaceuticals Inc. was incorporated in 1999 and is headquartered in Nashville, Tennessee.
Cumberland Pharmaceuticals Inc. (CPIX) trades around $6.61 per share, with a market capitalization of $99.04M and a market-rank of 3979. The current price sits within a broader forecast that shows a path from neutral in 2026 to progressively stronger upside through the coming years.
The year 2026 carries a neutral sentiment with a min of $2.80, an average of $6.61, and a max of $9.96. From 2027 onward, the outlook shifts to bullish with a sequence of higher averages and rising momentum.
A major floor 54.3% below — a decisive break under it would weaken the trend.
The nearest floor, 16.6% below — buyers have tended to step in here.
The nearest ceiling, 17.5% above — a clean break opens room to run.
A major ceiling 34.4% above — clearing it would confirm fresh momentum.
Key CPIX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CPIX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $6.78 | Sell | $6.77 | Sell |
| MA 10 | $6.98 | Sell | $6.84 | Sell |
| MA 20 | $6.81 | Sell | $6.76 | Sell |
| MA 50 | $6.27 | Buy | $6.20 | Buy |
| MA 100 | $4.96 | Buy | $5.45 | Buy |
| MA 200 | $4.21 | Buy | $4.70 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 50.43 | Neutral |
| Stoch RSI (14) | 1.11 | Buy |
| CCI (20) | -21.00 | Neutral |
| Williams %R (14) | -94.35 | Info |
| MACD (12,26,9) | -0.10 | Sell |
| ROC (12) | -14.36 | Sell |
| Bollinger %B (20,2) | 0.44 | Neutral |
| Stochastic %K (14) | 5.65 | Buy |
| TRIX (15) | 0.64 | Buy |
| Awesome (5,34) | 0.27 | Buy |
| Ultimate (7,14,28) | 42.32 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | 28.00 | Buy |
| Hull MA (9) | 6.62 | Buy |
| ADX (14) | 14.26 | Neutral |
| ATR (14) | 0.31 | Info |
The 30-day technical picture is bullish in aggregate, with room to move toward resistance on strength and potential pullbacks near support. The RSI14 is 50, indicating a balanced near-term momentum. The stock trades above the 50-day simple moving average of $6.07 and well above the 200-day simple moving average of $4.11, suggesting a constructive trend.
Support is identified at $5.48 and resistance at $7.85, with the 30-day price range spanning $4.66 to $9.39. volatility remains elevated, with annualized volatility at 100%. These readings point to a flexible near-term path with upside potential but notable sensitivity to price swings.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.80 | $6.68 | $9.70 | 0% | Neutral | |
| $7.14 | $9.58 | $13.86 | +43% | Bullish | |
| $8.22 | $11.64 | $17.86 | +74% | Bullish | |
| $7.32 | $10.84 | $17.39 | +62% | Bullish | |
| $8.20 | $12.64 | $21.06 | +89% | Bullish | |
| $10.82 | $17.32 | $29.80 | +159% | Bullish | |
| $13.21 | $21.89 | $38.75 | +228% | Bullish | |
| $16.08 | $27.58 | $50.07 | +313% | Bullish | |
| $15.79 | $27.97 | $51.98 | +319% | Bullish | |
| $14.87 | $27.19 | $51.63 | +307% | Bullish | |
| $25.80 | $54.89 | $113.86 | +722% | Bullish | |
| $55.61 | $123.58 | $284.23 | +17.5x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $2.80 | $6.68 | $8.04 | +0.00% |
| September 2026 | $5.62 | $6.79 | $8.53 | +1.61% |
| October 2026 | $5.94 | $7.26 | $9.29 | +6.97% |
| November 2026 | $5.91 | $7.30 | $9.47 | +0.53% |
| December 2026 | $5.92 | $7.38 | $9.70 | +1.11% |
Click any year to see its month-by-month CPIX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Cumberland Pharmaceuticals Inc.'s 2026 outlook centres on $6.68, within a $2.80 to $9.70 range. That marks a 0% change versus current levels. A consolidation phase looks the most probable path here.
By 2027, CPIX could reach as high as $13.86, with a base case around $9.58 and support toward $7.14 — roughly +43% from $6.68. Momentum favours further upside here.
Expect CPIX to range from $8.22 to $17.86 through 2028. The $11.64 average target implies a +74% move from current prices. That is up +21% on the projected 2027 average. Buyers look set to stay in control over this stretch.
The CPIX price prediction for 2029 points to an average of $10.84 (low $7.32, high $17.39) — a potential gain of +62% on today's $6.68. Momentum favours further upside here.
In 2030, CPIX is projected to trade between $8.20 and $21.06, averaging $12.64 — a potential gain of +89% from today's $6.68. That is up +17% on the projected 2029 average. Buyers look set to stay in control over this stretch.
Cumberland Pharmaceuticals Inc.'s 2031 outlook centres on $17.32, within a $10.82 to $29.80 range. That is up +37% on the projected 2030 average. That marks a +159% change versus current levels. Momentum favours further upside here.
By 2032, CPIX could reach as high as $38.75, with a base case around $21.89 and support toward $13.21 — roughly +228% from $6.68. Buyers look set to stay in control over this stretch.
Expect CPIX to range from $16.08 to $50.07 through 2033. The $27.58 average target implies a +313% move from current prices. That is up +26% on the projected 2032 average. Momentum favours further upside here.
The CPIX price prediction for 2034 points to an average of $27.97 (low $15.79, high $51.98) — a potential gain of +319% on today's $6.68. Buyers look set to stay in control over this stretch.
In 2035, CPIX is projected to trade between $14.87 and $51.63, averaging $27.19 — a potential gain of +307% from today's $6.68. That is -3% versus the projected 2034 average. Momentum favours further upside here.
Cumberland Pharmaceuticals Inc.'s 2040 outlook centres on $54.89, within a $25.80 to $113.86 range. That is up +102% on the projected 2035 average. That marks a +722% change versus current levels. Buyers look set to stay in control over this stretch.
By 2050, CPIX could reach as high as $284.23, with a base case around $123.58 and support toward $55.61 — roughly +17.5x from $6.68. Momentum favours further upside here.
Investing $1,000 in CPIX today (≈ 149.700599 CPIX) could be worth
$18,499.7
+$17,499.7 (+1750%) by 2050 · US Dollar
Based on the average projected CPIX price of $123.58 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CPIXwould be worth at today's price.
$1,000 invested in CPIX on Jul 31, 2025 (≈ 289.855068 CPIX) would be worth
$1,936.23
+$936.23 (+93.6%) today · 1.94× · US Dollar
Based on a CPIX entry price of $3.45 vs. today's $6.68.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $6.61 | $1,010.59 | +1.1% |
| 1 month ago | $7.13 | $936.89 | -6.3% |
| 3 months ago | $4.36 | $1,532.11 | +53.2% |
| 6 months ago | $3.86 | $1,730.57 | +73.1% |
| 1 year ago | $3.45 | $1,936.23 | +93.6% |
| All time (5.0y) ago | $3.03 | $2,204.62 | +120.5% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CPIX forecast.
Our base-case forecast reaches $13.00 around 2031.
Implied market cap at $13.00: $194.78M
The multi-year forecast portrays a clear progression higher in average values and a substantial rise in upside potential. By 2030, the average price is projected to $12.15 with an 83.9% ROI and bullish sentiment. The forecast continues to a 2040 average of $52.02 and a 686.9% ROI, keeping a bullish tone.
By 2050 the average is projected at $123.64 with a remarkable 1770.5% ROI, underscoring strong long-run upside while acknowledging the inherent uncertainty of such estimates. These figures imply a sustained growth trajectory across the late 2020s into the 2040s and beyond, but they are estimates and not guarantees, and they carry the usual caveats about market uncertainties and execution risk.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $12.15, with a min of $7.54 and a max of $21.04, and an ROI of 83.9% with bullish sentiment.
From 2027 onward, the outlook is bullish with rising average prices and positive ROI (e.g., 2027 avg $9.59, ROI 45.1%; 2030 avg $12.15, ROI 83.9%), though the 2026 period is neutral and these are estimates, not guarantees.
Yes. The 2050 forecast shows a max of $284.37 and an average of $123.64 with a min of $55.64, meaning surpassing $100 is within the projected range although it remains an estimate rather than a promise.
The current price is $6.61 and the market cap is $99.04M.
The 30-day range is from $4.66 to $9.39.
Cumberland Pharmaceuticals Inc. Community Discussion
0Share your Cumberland Pharmaceuticals Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.